Skip to content

Toshihiko Matsumoto

3 papers in the library · 74 citations · publishing 2006-2023

Papers

Sort Most recent Most cited

Risk factors for cannabis use disorders and cannabis psychosis in Japan: Second report of a survey on cannabis-related health problems among community cannabis users using social networking services.

Neuropsychopharmacology Reports March 1, 2023 Yuji Masataka, Takeshi Sugiyama, Yoshiyuki Akahoshi et al.

To determine the risk factors for cannabis use disorders and cannabis psychosis in Japan based on a 2021 online survey among Japanese users of social network services. The 3142 respondents who had used cannabis within the preceding year were categorized into two groups based on the development of cannabis use disorder and/or cannabis psychosis. Analyses were performed to determine these...

2C‐T‐4 intoxication: Acute psychosis caused by a designer drug

Psychiatry and Clinical Neurosciences April 1, 2008 Miho Miyajima, Toshihiko Matsumoto, Shigeo Ito 45 citations

DESIGNER DRUG ABUSE is a serious problem in Japan.1 Recently we encountered an acute intoxication in an emergency setting involving one such drug, which has never been reported as a clinical case anywhere. A 40-year-old man, with no previous history of mental disorder, although having had experiences of occasional use of street drugs, was brought to the emergency room by his mother. He was in a...

DESIGNER DRUGS AS A CAUSE OF HOMICIDE

Addiction October 10, 2006 Toshihiko Matsumoto, Takayuki Okada 29 citations

'Foxy' is a widely used street name for a hallucinogenic drug containing the tryptamine derivative 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). The US Drug Enforcement Administration classified 5-MeO-DIPT as a Schedule I substance in 2004 [1]; the Japanese Ministry of Health, Labour and Welfare has also restricted this substance since April 2005, according to the Narcotics and...